ALERT-Rx-FDA-DRUG SAFETY-GILENYA (FINGOLIMOD)-MULTIPLE SCLEROSIS

U.S. Food & Drug Administration Drug Safety Communication

Gilenya (fingolimod): Drug Safety Communication – Severe Worsening of Multiple Sclerosis After Stopping the Medicine

  • FDA is warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse than before the medicine was started or while it was being taken. This MS worsening is rare but can result in permanent disability
  • Gilenya is one of several medicines approved to treat a form of MS called relapsing MS, which are periods of time when MS symptoms get worse. The medicine was approved in the United States in 2010
  • For FDA recomendations-health care providers & patients please see,

https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm626264.htm?utm_campaign=FDA%20MedWatch%20-%20Gilenya%20%28fingolimod%29%3A&utm_medium=email&utm_source=Eloqua